Remote loading of sparingly water-soluble drugs into liposomes
The present invention provides liposome compositions containing sparingly soluble drugs that are used to treat life-threatening diseases. A preferred method of encapsulating a drug inside a liposome is by remote or active loading. Remote loading of a drug into liposomes containing a transmembrane electrochemical gradient is initiated by co-mixing a liposome suspension with a solution of drug, whereby the neutral form of the compound freely enters the liposome and becomes electrostatically charged thereby preventing the reverse transfer out of the liposome. There is a continuous build-up of compound within the liposome interior until the electrochemical gradient is dissipated or all the drug is encapsulated in the liposome. However, this process as described in the literature has been limited to drugs that are freely soluble in aqueous solution or solubilized as a water-soluble complex. This invention describes compositions and methods for remote loading drugs with low water solubility (<2 mg/mL). In the preferred embodiment the drug in the solubilizing agent is mixed with the liposomes in aqueous suspension so that the concentration of solubilizing agent is lowered to below its capacity to completely solubilize the drug. This results in the drug precipitating but remote loading capability is retained. The process is scalable and, in liposomes in which the lipid composition and remote loading agent are optimized, the resulting drug-loaded liposomes are characterized by a high drug-to-lipid ratios and prolonged drug retention when the liposome encapsulated drug is administered to a subject.
1. A method of remotely loading a precipitate of a solid active agent across liposomal membranes of liposomes, into an internal aqueous medium of the liposomes, from an aqueous suspension comprising the precipitate of the solid active agent and the liposomes, the solid active agent having a water solubility of less than 2 mg/mL, the method comprising:
(a) preparing an aqueous suspension of the liposomes having a proton or an ion gradient across the liposome membrane;
(b) preparing a precipitate of the solid active agent: and
(c) forming a loading suspension of (a) and (b), and incubating the loading suspension, thereby remotely loading the precipitate of the solid active agent across the liposomal membrane into the internal aqueous medium of the liposomes by a transmembrane proton- or ion-gradient, forming a suspension of product liposomes encapsulating the precipitate of the solid agent.
2. A method of remotely loading a precipitate of a solid active agent across liposomal membranes of liposome, into an internal aqueous medium of the liposomes, from an aqueous suspension comprising a precipitate of the solid active agent and the liposomes, the solid active agent having a water solubility of less than 2 mg/mL, the method comprising:
(a) contacting an aqueous suspension of the liposomes having a proton or an ion gradient across the liposome membrane with the precipitate of the solid active agent, forming a loading suspension; and
(b) incubating the loading suspension, thereby remotely loading the precipitate of the solid active agent across the liposomal membrane into the internal aqueous medium of the liposomes by a transmembrane proton- or ion-gradient, forming a suspension of product liposomes encapsulating the precipitate of the solid agent.
3. A method of remotely loading a precipitate of a solid active agent across a liposomal membranes of liposomes, into an internal aqueous medium of the liposomes, from an aqueous suspension comprising a precipitate of the solid active agent and the liposomes, the solid active agent having a water solubility of less than 2 mg/mL, the method comprising:
(a) contacting an aqueous suspension of the liposomes having a proton or an ion gradient across the liposome membrane with the precipitate of the solid active agent, forming a loading suspension; and
(b) incubating the loading suspension, thereby remotely loading the precipitate of the solid active agent across the liposomal membrane into the internal aqueous medium of the liposomes by a transmembrane proton- or ion-gradient, forming a suspension of product liposomes encapsulating the precipitate of the solid agent,
wherein
encapsulation efficiency of the method, defined as amount of the precipitate of the solid agent transferred into the internal aqueous medium of the liposomes divided by amount of the precipitate of the solid active agent in the loading suspension multiplied by 100%, is at least 50%.
4. The method of any of claims 1 to 3 , wherein light scattering at 600 nm of the aqueous suspension comprising a precipitate of the solid active agent is greater than that of the suspension of product liposomes.
5. The method according to any of claims 1 to 3 , the liposomes having a liposome membrane selected from molar ratios:
(i) HSPC/cholesterol/PEG-DSPE (55/40/5); and
(ii) sphingomyelin/cholesterol/PEG-DSPE (55/45/2.8): and
(iii) DSPC/DSPG/cholesterol (70/20/10); and
(iv) POPC/cholesterol/PEG-DSPE (57/40/3); and
(v) POPC/POPG/cholesterol (70/20/10).
6. The method according to any of claims 1 to 3 , wherein the gradient is a gradient of a member selected from a proton, amine or a metal compound of a member selected from a carboxylate, a sulfate, a sulfonate, a phosphate a phosphonate and an acetate.
7. The method according to claim 5 , wherein the gradient is a gradient of a member selected from ammonium sulfate, triethylammonium sulfate, ammonium glucuronate, ammonium sucrose octasulfate, triethylammonium dextran sulfate, ammonium dextran sulfate, calcium acetate, magnesium acetate, ammonium chloride and citric acid.
8. The method according to any of the claims 1 to 3 , wherein the liposomes are from about 40 nm to about 200 nm in diameter.
9. A pharmaceutical formulation of the product liposomes of any claims 1 to 3 , comprising said product liposomes and a pharmaceutically acceptable excipient.
10. The method according to any of claims 1 to 3 , wherein the solid active agent is carfilzomib and is loaded into the liposome at a ratio of about 60 mg of the carfilzomib to from about 90 mg to about 200 mg of lipid.